Daewon Pharmaceutical 19% surge highlights biotech stocks amid expectations for Hanmi technology exports

8In the day’s trading session, Daewon Pharmaceutical’s share price rose 19% on expectations for a new obesity drug. During the same period, interest focused on related stocks amid major technology-export news and positive developments for the pharmaceutical sector. Some reports said Daewon Pharmaceutical showed relative strength even during a sharp market decline. Hanmi Pharmaceutical announced or was assessed as having greater potential for additional technology exports following its contract with Eli Lilly. Hana Securities raised its target price for Hanmi Pharmaceutical to reflect the possibility of additional technology exports. Interest increased as the company’s announcement and the securities firm’s assessment emerged at the same time. Samsung C&T was assessed as having an inexpensive valuation despite its share price having risen. Hana Securities was reported to have raised its target price for Samsung C&T. The assessment was based on a judgment of its current value compared with its share price. T-Robotics said it had won the Chapek Award in China. The company introduced the award as recognition of its potential to expand into physical AI. The company filed a disclosure regarding the award. Across the market, warnings were raised that the KOSPI could fall by 20%. Reports said market volatility was expanding and investor sentiment had weakened. Many stocks showed movements sensitive to volatility. Reports gathered that day said expectations for technology exports and company-specific award and valuation news increased differentiation among stocks. Investors need to check the relevant disclosures and securities-firm reports. Market warning reports indicated an overall increase in volatility.